



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.72
Trade Time:	6:30 PM ET 04/26/18
Change:	0.12 ▲ (7.500%)
Day Range	1.59 - 1.76
52-Week Range	1.42 - 4.84
Volume	1,691,914

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 04/26/18**
[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- 03/13/18**
[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- 03/12/18**
[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)
- 02/12/18**
[Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers \(ASCO GU\) 2018 Annual Meeting](#)
- 02/08/18**
[Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 \(Archexin®\) for the treatment of Hepatocellular Carcinoma](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- 03/09/18**
[Annual Report \(10-K\)](#)
- 04/23/18**
[Proxy Statement \(DEF 14A\)](#)
- 11/03/17**
[Quarterly Report \(10-Q\)](#)
- 08/04/17**
[Quarterly Report \(10-Q\)](#)
- 05/03/17**
[Quarterly Report \(10-Q\)](#)